Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

The Company believes that these next generation drug candidates fit synergistically with Telix’s therapeutics pipeline ... with international operations in the United States, Canada, Europe (Belgium ...

Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. A biotechnology company in Research Triangle Park has taken a major step to develop a new option for ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock has declined 7.4% over the past three months. However, a closer look at its sound ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. STORY HIGHLIGHTS FDA clears United Therapeutics for human trials of pig-to-human kidney transplants.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...